![LIMMATECH BIOLOGICS AG](https://www.impactnews-wire.com/wp-content/uploads/2023/10/hlgxov2pose1ingt3i3v.webp)
LimmaTech Biologics Raises $37 Million Series A to Advance Its Pipeline of Vaccines Against Multidrug-Resistant Bacterial Infections
October 09, 2023 04:00 AM Eastern Daylight Time SCHLIEREN, Switzerland – LimmaTech Biologics AG today announced the closing of a USD 37 million (CHF 33 million) Series A financing round co-led by Adjuvant Capital, AXA IM Alts, and the Novo Holdings REPAIR Impact Fund. The proceeds will enable LimmaTech to advance its proprietary technology platform and accelerate its pipeline of preclinical and clinical vaccine candidates against … Continue reading LimmaTech Biologics Raises $37 Million Series A to Advance Its Pipeline of Vaccines Against Multidrug-Resistant Bacterial Infections